biotech · Presbyopia · Eye Diseases · LENZ
LENZ Therapeutics
LENZ Therapeutics is a biotech organization headquartered in San Diego, USA. It trades on NYSE under ticker LENZ. Primary therapeutic focus areas include Presbyopia, Eye Diseases. NovaPharmaNews links 5 clinical program(
Company details
- Status
- Public
- HQ
- San Diego, USA
- Employees
- 176
- Programs
- 5
- Drugs
- 6
- Patents
- 20
Quick answer
LENZ Therapeutics is a biotech organization headquartered in San Diego, USA. It trades on NYSE under ticker LENZ. Primary therapeutic focus areas include Presbyopia, Eye Diseases. NovaPharmaNews links 5 clinical program(s), 1 drug profile(s), and 20 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 1 (2), phase 2 (2), phase 3 (1).
Company snapshot
LENZ Therapeutics is a pharmaceutical company developing innovative ophthalmic pharmaceutical products that improve vision. Our lead product is VIZZ, an aceclidine based eye drop designed to restore the loss of near vision associated with presbyopia. Presbyopia impacts almost two billion people globally and more than 120 million people in the US. LENZ Therapeutics is headquartered in San Diego, Ca
- 1 approved product(s) across US/EU regulatory metadata.
- 5 active pipeline program(s) linked via ClinicalTrials.gov.
- 20 US patent(s) indexed to this assignee profile.
Public regulatory, clinical, patent, and corporate records for LENZ Therapeutics. Not investment advice.
Top assets
Lead pipeline drugs
- approved
- Marketed / approved
- Marketed / approved
- Marketed / approved
Active clinical programs
- Phase 3
- Phase 2
- Phase 2
- Phase 1
Momentum
Proprietary activity score for LENZ Therapeutics.
1 active signal
Signal breakdown
- Clinical trials
- Nova articles
- Patents filed
- FDA actions
- SEC filings
- Conference presentations
- Pipeline advances
Recent activity
Latest pipeline, patent, and corporate events for LENZ Therapeutics.
- Clinical update
- Clinical update
- Clinical update
LNZ101 (Aceclidine /Brimonidine) ophthalmic solution — Phase 1
- Clinical update
Aceclidine+Brimonidine combination ophthalmic solution — Phase 3
- Clinical update
Quick answers
Common questions about this sponsor — for analysts and search.
-
What is LENZ Therapeutics?
-
Is LENZ Therapeutics publicly traded?
-
What drugs does LENZ Therapeutics develop or market?
-
What are the latest developments for LENZ Therapeutics?
-
What therapeutic areas does LENZ Therapeutics focus on?
Therapeutic focus
Therapeutic area distribution
Pipeline concentration by therapeutic area from linked clinical programs.